TCGA-44-3917-01A-01R-A278-07
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 33
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.400
- E2F_TARGETS+0.340
- PROTEIN_SECRETION+0.310
- PANCREAS_BETA_CELLS+0.290
- MYC_TARGETS_V1+0.280
- G2M_CHECKPOINT+0.230
- SPERMATOGENESIS+0.210
- UNFOLDED_PROTEIN_RESPONSE+0.180
- BILE_ACID_METABOLISM+0.170
- DNA_REPAIR+0.160
Top 10 suppressed
- APICAL_SURFACE-0.550
- WNT_BETA_CATENIN_SIGNALING-0.500
- NOTCH_SIGNALING-0.470
- HEDGEHOG_SIGNALING-0.430
- TNFA_SIGNALING_VIA_NFKB-0.430
- APICAL_JUNCTION-0.400
- P53_PATHWAY-0.390
- MYOGENESIS-0.370
- HYPOXIA-0.360
- ESTROGEN_RESPONSE_EARLY-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-EW-A1P0-01A-11R-A144-07 | — | B | 0.861 |
| 2 | MNG87 | — | — | 0.860 |
| 3 | TCGA-91-8499-01A-11R-2403-07 | — | cohortMD1 | 0.849 |
| 4 | SJEPD030948_D1.RNA-Seq | EPN | EPN Tumor | 0.848 |
| 5 | SRR1797275 | — | cohortSC | 0.847 |
| 6 | MNG832 | — | — | 0.837 |
| 7 | R356 | — | — | 0.832 |
| 8 | SRR1797285 | — | cohortSC | 0.829 |
| 9 | 20110028.LumB | — | B | 0.829 |
| 10 | SRR12202421 | — | — | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.140 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.080 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.030 | Idelalisib | — uncovered |